NEW ORLEANS — In this video perspective, Samer Al Hadidi, MD, MS, FACP, discusses presentations from the ASH Annual Meeting and Exposition that focus on treatments that yielded better tolerance for patients with multiple myeloma.
In one randomized phase 3 trial, initial therapy without steroids seemed comparable to the regimen that included steroids in older, frail patients with multiple myeloma, according to Al Hadidi, assistant professor at the University of Arkansas for Medical Sciences.
“This is important to try to tailor therapies for our patients,” he told Healio.
Another
